Ozone has been used outside the United States to treat disc herniations for over 15 years and there are over 40 peer-reviewed papers documenting over 8,000 patients. Treatment with ozone is not FDA approved and the Triojection® System is not available in the United States.
Minimus Spine developed the Triojection System to elevate the standard for performing an ozone injection. Triojection is a patented system that creates ozone and measures its concentration, within a sterile, single-use syringe cartridge. Triojection has advantages in terms of sterility and confidence in the concentration of gas delivered to the patient, as well as material compatibility. All of these improvements are vital to the advancement of this technique.
Minimus Spine and the Triojection system have received the necessary certifications to commercialize Triojection in Europe (ISO 13485 Certification and EC Certificate). British Standards Institute is Minimus Spine’s Notified Body.
Minimus Spine seeks to improve patient care and cut health care costs by reducing the number of steroid injections and surgeries